

## Special Issue

# Novel Developments in Invasive Lobular Breast Cancer: Diagnosis, Prognosis and Therapy

### Message from the Guest Editors

Invasive lobular carcinoma is the most common special subtype of invasive breast carcinoma. In addition to its specific morphology, it has different clinical, imaging, molecular, and treatment features compared to invasive breast carcinoma of no special type, as well as other special histologic subtypes. Recent developments in this field include the recognition of novel subtypes. We are pleased to invite you to contribute articles to this Special Issue, which aims to add to existing knowledge concerning the diagnosis, prognosis, and treatment of invasive lobular breast cancer. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: clinical, imaging, pathologic, molecular, and treatment features of invasive lobular carcinoma. We look forward to receiving your contributions.

### Guest Editors

Dr. Lubna Khaldi

Department of Pathology, Saint Savvas Anticancer Hospital of Athens, 11522 Athens, Greece

Dr. Nektarios Koufopoulos

Second Department of Pathology, Medical School, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece

### Deadline for manuscript submissions

closed (1 March 2025)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/174314](https://mdpi.com/si/174314)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)